NewEdge Wealth LLC Decreases Stake in Bristol Myers Squibb Company $BMY

NewEdge Wealth LLC reduced its position in Bristol Myers Squibb Company (NYSE:BMY) by 38.2% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 15,813 shares of the biopharmaceutical company’s stock after selling 9,769 shares during the period. NewEdge Wealth LLC’s holdings in Bristol Myers Squibb were worth $959,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb during the second quarter worth $25,000. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at $25,000. Physician Wealth Advisors Inc. raised its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 202 shares during the period. Bayban purchased a new stake in Bristol Myers Squibb during the 4th quarter worth about $31,000. Finally, EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb in the 4th quarter worth about $32,000. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

BMY has been the topic of several analyst reports. Cantor Fitzgerald reiterated a “neutral” rating and set a $54.00 price target on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Weiss Ratings cut shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 16th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday. Eight investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $61.25.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $62.56 on Tuesday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.44. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The stock has a market cap of $127.75 billion, a P/E ratio of 17.57, a price-to-earnings-growth ratio of 0.18 and a beta of 0.23. The firm’s fifty day moving average price is $57.59 and its 200-day moving average price is $58.12.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.